Skip navigation
  • Home
  • Browse
    • Communities
      & Collections
    • Browse Items by:
    • Publication Date
    • Author
    • Title
    • Subject
    • Department
  • Sign on to:
    • My MacSphere
    • Receive email
      updates
    • Edit Profile


McMaster University Home Page
  1. MacSphere
  2. Open Access Dissertations and Theses Community
  3. Open Access Dissertations and Theses
Please use this identifier to cite or link to this item: http://hdl.handle.net/11375/12661
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorHassell, John A.en_US
dc.contributor.advisorTrigatti, Bernardoen_US
dc.contributor.advisorKaren Mossman, Jonathan Bramsonen_US
dc.contributor.authorLessan, Alien_US
dc.date.accessioned2014-06-18T17:00:19Z-
dc.date.available2014-06-18T17:00:19Z-
dc.date.created2012-10-01en_US
dc.date.issued2012-10en_US
dc.identifier.otheropendissertations/7528en_US
dc.identifier.other8592en_US
dc.identifier.other3359935en_US
dc.identifier.urihttp://hdl.handle.net/11375/12661-
dc.description.abstract<p>Based on the cancer stem cell (CSC) model, tumors develop as a hierarchy, much like normal tissue. At the apex, CSCs are capable of self-renewal and differentiating into non-tumorigenic cells that form the bulk of the tumor. CSCs have been isolated for many types of cancer based on cell surface marker expression. For instance in human breast carcinoma, the CD44+ CD24-/low EpCAM+ population are enriched in CSCs. These cells are more resistant to traditional chemo and radiation therapy relative to the bulk of the tumor. As such, many believe CSCs to be responsible for relapse and metastasis events. Hence, a more targeted therapy towards breast CSCs can prove to be very effective. EpCAM has been shown to be a reliable, albeit not exclusive, marker of breast CSCs. A more thorough understanding of EpCAM’s function can provide new angles for designing therapeutic agents. Originally thought to be a mere adhesion molecule, EpCAM is now known to derive a signalling pathway that promotes transcription in its target genes. We aimed to provide further insight into this novel pathway, by manipulating EpCAM’s expression and function in MCF7 breast cancer cell line. We designed a dominant negative allele of the EpCAM protein to hinder the activity of the endogenous EpCAM. However, this transgene offered no significant effect on our cell line. Furthermore, we used RNA interference technology to reduce EpCAM expression. The introduction of the EpCAM short hairpin RNA constructs into our cell line had inhibitory effects on transcription reporter expression, cellular growth, adherent colony and unattached sphere formation. The inhibition of EpCAM in MCF7 spheres was followed by signs of cell death, differentiation and an epithelial mesenchymal transition process. Sphere cultures are used because they are enriched in cancer stem cells. The adverse effects of EpCAM inhibition in MCF7 spheres provides further evidence as to the role of this protein in cancer stem cells.</p>en_US
dc.subjectBreast Canceren_US
dc.subjectCancer Stem Cellen_US
dc.subjectEpCAMen_US
dc.subjectEMTen_US
dc.subjectBiochemistryen_US
dc.subjectMolecular Biologyen_US
dc.subjectMolecular geneticsen_US
dc.subjectBiochemistryen_US
dc.titleStrategies to Investigate the Role of EpCAM in Cancer Stem Cells of Breast Cancer Cell Linesen_US
dc.typethesisen_US
dc.contributor.departmentBiochemistryen_US
dc.description.degreeMaster of Science (MSc)en_US
Appears in Collections:Open Access Dissertations and Theses

Files in This Item:
File SizeFormat 
fulltext.pdf
Open Access
4.17 MBAdobe PDFView/Open
Show simple item record Statistics


Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.

Sherman Centre for Digital Scholarship     McMaster University Libraries
©2022 McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L8 | 905-525-9140 | Contact Us | Terms of Use & Privacy Policy | Feedback

Report Accessibility Issue